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Abstract
Large-scale epigenome-wide association meta-analyses have identified multiple ‘signatures’’ of smoking. Drawing on
these findings, we describe the construction of a polyepigenetic DNA methylation score that indexes smoking
behavior and that can be utilized for multiple purposes in population health research. To validate the score, we use
data from two birth cohort studies: The Dunedin Longitudinal Study, followed to age-38 years, and the Environmental
Risk Study, followed to age-18 years. Longitudinal data show that changes in DNA methylation accumulate with
increased exposure to tobacco smoking and attenuate with quitting. Data from twins discordant for smoking behavior
show that smoking influences DNA methylation independently of genetic and environmental risk factors.
Physiological data show that changes in DNA methylation track smoking-related changes in lung function and gum
health over time. Moreover, DNA methylation changes predict corresponding changes in gene expression in pathways
related to inflammation, immune response, and cellular trafficking. Finally, we present prospective data about the link
between adverse childhood experiences (ACEs) and epigenetic modifications; these findings document the
importance of controlling for smoking-related DNA methylation changes when studying biological embedding of
stress in life-course research. We introduce the polyepigenetic DNA methylation score as a tool both for discovery and
theory-guided research in epigenetic epidemiology.
Introduction
Tobacco smoking is the greatest health hazard in the
modern world. Smoking is associated with practically
every risk factor known to impact health and with
numerous clinical endpoints1. As such, uncovering
methods to identify and quantify the biological mechan-
isms through which tobacco smoking exerts its effects is
of critical public health importance.
One such mechanism is DNA methylation. Smoking is
known to exact pervasive alterations on the blood epi-
genome2–5. Epigenome-wide association studies (EWAS)
of DNA methylation have identified thousands of CpG
sites differentially methylated in smokers, though the
significance of these discoveries for population health
science remains uncertain. If DNA methylation changes
accumulate with increased exposure and attenuate with
sustained abstinence, DNA methylation analysis could
provide clinicians and researchers with a biomarker of
smoking-associated health risk.
Some attempt has been made to capture these manifold
DNA methylation differences into single, tangible bio-
markers describing various aspects of smoking-related
behavior and outcomes. At the simplest level, DNA
methylation level at a single CpG site within AHRR
(described by Illumina array probe ID cg05575921) has
been shown to discriminate between adult non-smokers
and current-smokers6,7, and former- from never-
smokers8, while other multi-probe scores have also been
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developed to assess various phenotypes, ranging from
exposure to maternal smoking9–11 to smoking-related
mortality12. However, the suitability of these scores to
index generalized smoking phenotypes is unknown, since
these metrics are usually developed and tested in one
specific population at one point in time with one specific
outcome. Additionally, temporal dynamics of composite
DNA methylation metrics cannot be assessed using cross-
sectional designs.
Longitudinal repeated-measures analysis of blood DNA
methylation in smokers and non-smokers followed over
time is needed to test (a) if further accumulation of
exposure in smokers is reflected in accumulating changes
to DNA methylation, and (b) if cessation and abstinence
are associated with reversal of these changes. Finally, data
are needed that observe organ system damage caused by
smoking in order to test if a DNA methylation biomarker
measures not just smoking behavior, but substantive
health consequences of tobacco exposure.
Here, we address four major themes relevant to the
relationship between tobacco smoking and DNA methy-
lation. First, draw on published EWAS findings of
smoking to construct a DNA methylation-based algo-
rithm (Smoking methylation PolyEpigenetic Score,
SmPEGS) and test its association with cross-sectional
smoking phenotypes. Second, we examine the hypothesis
that tobacco smoking has causal effects on DNA methy-
lation in blood via investigation of (a) SmPEGS among
twins discordant for smoking, and (b) the pattern of
change over time in SmPEGS for those who either
increase or cease tobacco consumption, or become nico-
tine dependent. In addition, we examine the relationship
between SmPEGS and gene expression profiles in those
who do, and do not, smoke in an attempt to uncover
potential mechanistic influences of SmPEGS. Third, we
analyze longitudinal repeated-measures data on lung
function and periodontal disease to test if smoking-
associated DNA methylation could provide a biomarker of
biological damage arising from tobacco exposure. Fourth,
to demonstrate a potential application of polyepigenetic
scores, we conduct EWAS of adverse childhood experi-
ences, an exposure thought to have long-term impacts on
health via biological embedding. We examine the con-
founding effects of tobacco smoking in DNA methylation
research and demonstrate the potential of utilizing the
SmPEGS in lieu of observational smoking data as a cov-
ariate to reduce spurious associations in studies of the
effects of early adversity on health.
We address these themes using data from two cohorts.
The first is the Dunedin Longitudinal Study, a long-
itudinal birth cohort of 1037 individuals born in 1972–73
and followed repeatedly until the latest assessment at age-
38 years. Study members gave blood for DNA analysis
first at age-26, and 12 years later when they were aged 38.
The second cohort is the E-Risk longitudinal twin study, a
cohort of 2232 twins (56% MZ) born in 1994. E-Risk
Study members gave blood for DNA analysis at the most
recent assessment, aged 18 years.
Materials and methods
Detailed information about sampling, measurement,
and statistical analysis is available in the Supplementary
materials.
Sample
Dunedin Study
Participants were members of the Dunedin Long-
itudinal Study. Participants (N= 1037; 91% of eligible
births; 52% male) were all individuals born between April
1972 and March 1973 in Dunedin, New Zealand, who
were eligible based on residence in the province and who
participated in the first assessment at age 313. The cohort
represented the full range of socioeconomic status (SES)
in the general population of New Zealand’s South Island.
Assessments were carried out at birth and ages 3, 5, 7, 9,
11, 13, 15, 18, 21, 26, 32, and, most recently, 38 years,
(95% retention rate).
E-Risk Study
The Environmental Risk (E-Risk) Longitudinal Twin
Study, tracks the development of a 1994–1995 birth
cohort of 2232 British children14. Briefly, the E-Risk
sample was constructed in 1999 and 2000, when 1116
families (93% of those eligible) with same-sex 5-year-old
twins participated in home-visit assessments. This sample
comprised 56% monozygotic and 44% dizygotic twin
pairs, and sex was evenly distributed within zygosity (49%
male). The study sample represents the full distribution of
socioeconomic conditions in Great Britain. Assessments
were carried out at ages 5, 7, 10, 12, and, most recently, 18
years (93% retention rate).
Smoking history
Smoking behavior in Dunedin has been assessed
repeatedly between ages 15–38 years, including informa-
tion about quantity smoked, cessation, and second-hand
smoke exposure. In E-Risk, participants were interviewed
about their smoking history at age-18 years.
DNA methylation
In Dunedin, DNA was derived from peripheral blood
drawn at ages 26 and 38 years. In E-Risk, peripheral whole
blood was drawn at age-18 years. In both cohorts, DNA
methylation was measured using the Illumina Infinium
HumanMethylation450 BeadChip (“Illumina 450K array”;
Illumina, CA, USA).
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Gum health
Periodontal attachment loss was assessed at ages 26 and
38 in the Dunedin Study by calibrated dental examiners.
Lung function
Single-breath diffusing capacity for carbon monoxide
(DLco/VA) was assessed at ages 26 and 38 in the Dunedin
Study according to European Respiratory Society/American
Thoracic Society standards using a body plethysmograph
(CareFusion, Yorba Linda, CA). Measures were corrected
for hemoglobin, height, smoking within an hour of assess-
ment and sex15.
Gene expression
RNA was derived from peripheral blood drawn into
PAXGene RNA tubes at age-38 in Dunedin. Expression
data were generated from whole-blood RNA using the
Affymetrix PrimeView Human Gene Chip (Affymetrix,
CA, USA).
Adverse childhood experiences (ACEs)
The measured ACEs correspond to the ten sub-
categories of childhood adversity introduced by the U.S.
Centers for Disease Control & Prevention (CDC) Adverse
Childhood Experiences Study;16 i.e., three types of abuse
(emotional, physical, sexual), five types of household
challenges (household partner violence, household sub-
stance abuse, mental illness in household, loss of a parent
due to parental death, separation, or divorce, incarcera-
tion of a family member), and two types of neglect
(emotional, physical).
Statistical analysis
All analyses were performed in the R statistical pro-
gramming environment (version 3.4.2). In brief, linear
regression was used to test association between depen-
dent and independent variables, while in E-Risk, Gen-
eralized Estimating Equations (GEE) were used to account
for the clustering within families.
Code availability
Code available on request from corresponding author.
Results
A. Methylation polygenic scores were differentially
distributed in never-, former-, and current-smokers
We computed a smoking methylation polyepigenetic
score (SmPEGS) for tobacco exposure based on the 2623
CpG probes identified by Joehanes et al.2,11 in their
epigenome-wide meta-analysis of current vs. never
smoking (Supplementary Table S1). We calculated
SmPEGS values by multiplying the % methylation mea-
sured at a CpG site with the effect-size estimated for that
CpG by Joehanes et al.2 and then computing the average
across the set of CpGs. The resulting SmPEGSs were
differentially distributed in never-, former- and current-
smokers in the Dunedin and E-Risk cohorts. In the
Dunedin cohort, as compared to never-smokers (n= 405),
former-smokers (n= 233) had SmPEGSs on average
0.45 SD units higher [95%CI 0.33–0.58] and current-
smokers (n= 165) had SmPEGSs on average 1.65 SD
units higher [95%CI 1.51–1.80] (p < 0.001 for both com-
parisons; Fig. 1a). In the E-Risk cohort, as compared to
never-smokers (n= 1203), former-smokers (n= 57) had
SmPEGSs on average 0.21 SD units higher [95% CI
0.02–0.40] and current-smokers (n= 374) had SmPEGSs
on average 1.00 SD units higher [95% CI 0.87–1.13] (p=
0.03 for former-smokers; p < 0.001 for current-smokers;
Fig. 1b). Supplementary Fig. S2 shows SmPEGS success-
fully discriminated never- from both current- and ever-
smokers in both Dunedin and E-Risk (AUC range from
0.77–0.93).
Methylation polygenic scores tracked upwards with cumu-
lative cigarette consumption
Dunedin Study members have been interviewed
repeatedly about their smoking behavior since age
15 years17. We used these prospective data to calculate the
number of pack-years each Study member had smoked
through the most recent interview at age-38 years. At age-
38 years, for Dunedin Study members who had ever
smoked (n= 397), pack-years ranged from 0.05–38.75
(mean= 11.71, SD= 8.65). Those who had smoked more
pack-years had higher SmPEGS; each additional pack-year
smoked was associated with a 0.07 SD unit higher
SmPEGS [95% CI 0.06–0.08] (p < 0.001) (Fig. 1c).
Next, we turned to the 18-year-olds in the E-Risk
sample. At age-18 years, for E-Risk Study members who
had ever smoked (n= 431), pack-years ranged from
0.05–14.85 (mean= 2.04 SD= 1.76). Those who had
smoked more pack-years had higher SmPEGS; each
additional pack-year smoked was associated with a 0.1 SD
unit higher SmPEGS [95% CI 0.05–0.15] (p < 0.001),
similar to the 0.07-unit increase estimated in the Dunedin
data (Fig. 1d).
B. Tobacco smoking has independent causal effects on
DNA methylation
Smoking and DNA methylation polygenic scores are
heritable, but their association is not fully accounted for by
genetic variation
Using the twin design of the E-Risk Study18, we tested
genetic influences on smoking behavior. Consistent with
previous research19, we find a substantial proportion of
variation in pack-years smoked is under genetic influence
(rMZ= 0.69, rDZ= 0.45; additive genetic variance=
48.5% [95%CI 35.5–61.8%]; shared environmental
variance= 16.0% [95%CI 4.1–27.3%]; non-shared
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environmental variance= 35.5% [95% CI 31.8–39.7%];
Supplementary materials). In parallel, we found that a
substantial proportion of variation in SmPEGS is under
genetic influence (rMZ= 0.87, rDZ= 0.52; additive
genetic variance= 70.9% [95% CI 60.4–82.6%]; shared
environmental variance= 16.0% [95% CI 4.3–26.5%];
non-shared environmental variance= 13.1% [95% CI
11.7–14.6%]).
To test if genetic and shared environmental factors
might confound associations between tobacco exposure
and SmPEGS values, we studied differences between twins.
Specifically, we parsed the effect of pack-years smoked on
SmPEGS into between-twin and within-twin-pair effects
(Supplementary materials). Within-twin-pair differences
in pack-years among both DZ and MZ twins were sig-
nificantly associated with differences in SmPEGS, such
that the co-twin who smoked more had higher SmPEGS
(b= 0.18, [95% CI 0.10–0.25] p < 0.001). We found a
similar pattern when the analysis was repeated using only
MZ twins (b= 0.09, [95% CI 0.02–0.16] p= 0.01), indi-
cating the association could not be fully explained by
shared family-wide environmental or genetic factors.
Fig. 1 Distribution of SmPEGS across different smoking phenotypes in the Dunedin Study and the E-Risk Study. a (Dunedin Study) and b (E-Risk
Study) show the distribution in never-, former-, and current-smokers. Black bars represent mean values per group. c and d plot the association of
SmPEGS and smoking pack-years in study members who report any smoking in the Dunedin Study (c) and the E-Risk Study (d). The Dunedin Study
members were assessed at age-38, whereas the E-Risk Study members were assessed to age-18; hence their truncated years of potential smoking
compared to the Dunedin Study (x-axis). e plots the association of the change in pack-years smoked and change in SmPEGS in Study members who
report any smoking between ages 26 and 38 in the Dunedin Study. SmPEGS= Smoking Methylation Polygenic Score. SmPEGS are standardized to
mean= 0 and SD= 1 within each study
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Study members who smoked additional pack-years between
ages 26 and 38 experienced increase in their methylation
polygenic scores
Dunedin Study members provided DNA for analysis of
methylation at two time points, ages 26 and 38. To isolate
the effect of accumulating tobacco exposure on changes
in the methylome, we utilized the repeated-measures of
tobacco exposure and SmPEGS in the Dunedin Study. For
Study members who accumulated pack-years between
ages 26 and 38 (n= 280), we regressed change in SmPEGS
on the number of additional pack-years smoked. Com-
pared to their age-26 baseline, each additional pack-year
smoked between ages 26 and 38 years was associated with
a 0.05 SD unit increase in SmPEGS [95% CI 0.03–0.07]
(Fig. 1e). Accumulating tobacco exposure is reflected in
corresponding SmPEGS change.
Dunedin Study members who quit smoking between
methylation measurements at ages 26 and 38 experienced
a relative decline in their methylation polygenic scores
Figure 2 describes SmPEGS changes over time in four
groups; individuals who have never smoked, those who
quit smoking by age-26, those who quit between the two
assessments at ages 26 and 38, and those who were still
smoking at age-38. For individuals who had never smoked
or quit smoking by age-26, SmPEGS stayed relatively
static between ages 26 and 38 (mean SD unit change=
−0.04 [95% CI −0.1−0.01] for never-smokers, and −0.04
[95% CI −0.19–0.11] for those who quit by age-26). Those
individuals still smoking at age-38 experienced an
increase in their SmPEGS compared to age-26 (mean SD
unit change= 0.49 [95% CI 0.36–0.62]). However, those
who ceased smoking between ages 26 and 38 experienced
a relative decline in their SmPEGS over the same period
(mean SD unit change=−0.25 [95% CI −0.36 to −0.14]);
compared to the never-smokers, SmPEGS declined
0.21 SD units [95% CI 0.09–0.32]) over this period (Fig. 2).
Ceasing tobacco use is reflected in corresponding
SmPEGS recovery.
Dunedin Study members who are nicotine dependent have
higher methylation polygenic scores than non-dependent
smokers, and these scores are higher even after taking into
account density of tobacco consumption
In addition to the analysis of changes in SmPEGS
related to changes in smoking behavior over time, we
conducted analysis of changes in SmPEGS related to
changes in nicotine dependence using the Fagerstrom
Test of Nicotine Dependence (FTND) at ages 26 and
3817,20. This instrument is designed to test dependence on
nicotine by assessing, for example, criteria related to fre-
quent urges, valuing smoking most after abstinence, and
smoking density. Within those reporting current smoking
at age-26, nicotine-dependent Study members had
SmPEGS 0.43 SD units [95% CI 0.20–0.65] higher than
those not meeting criteria for nicotine dependence.
Similarly, at age-38, nicotine-dependent Study Members
had SmPEGS 0.61 SD units [95% CI 0.34–0.88] higher
than non-dependent Study Members. For individuals who
were never dependent, SmPEGS stayed relatively stable
between ages 26 and 38 (mean SD unit change=−0.04
[95% CI −0.12–0.05]). Those individuals who were
dependent only at age-26 experienced a slight decline in
their SmPEGS between ages 26 and 38 (mean SD unit
change= –0.12 [95% CI −0.36–0.11]). Those individuals
who were dependent at either age-38 only, or at both ages,
experienced relative increases in their SmPEGS between
ages 26 and 38 (mean SD unit change= 0.58 [95% CI
0.25–0.91] for age-38 only dependent individuals, and
0.60 [95% CI 0.33–0.87] for those who are dependent at
Fig. 2 Distribution of SmPEGS in the Dunedin Study at two time points across 12 years as a function of smoking history at age-38. The
figure shows Smoking methylation Polygenic Score (SmPEGS) were reduced for those who ceased to smoke between the two DNA methylation
assessments at ages 26 and 38. Black points represent means within each group connected by lines across the two assessment phases
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both ages). Compared to smokers who do not meet
diagnostic criteria at either age, SmPEGS increased
0.62 SD units [95% CI 0.30–0.93] and 0.63 SD units [95%
CI 0.40–0.87] in these two groups, respectively (Supple-
mentary Fig. S3). Because diagnosis of nicotine depen-
dence can rely heavily on density of smoking (dependent
smokers have on average 8.73 [95% CI 6.96–10.50] more
pack-years by age-38 than non-dependent smokers), and
because we have demonstrated SmPEGS increase with
cumulative tobacco consumption, we further tested
whether these associations with FTND were accounted
for by accelerated accumulation of tobacco between the
two ages. Compared to smokers who do not meet diag-
nostic criteria at either age, SmPEGS increased 0.37 SD
units [95% CI 0.02–0.73] and 0.35 SD units [95% CI
0.05–0.66] for individuals who were dependent at either
age-38 only, or at both ages, respectively, when change in
number of pack-years between age-26 and 38 was inclu-
ded as a covariate in the analysis. Diagnosis of nicotine
dependence predicts inter-age increases in SmPEGS in
these two groups even after controlling for accumulation
in pack-years between 26 and 38, suggesting the SmPEGS
indexes physical aspects of smoking behavior above and
beyond volume of cigarette consumption.
DNA methylation differences identified in epigenome-wide
association studies of smoking relate to gene expression
differences in both smokers and non-smokers
DNA methylation has been shown to play a role
in mediating gene expression, both directly and indir-
ectly21–24. We tested whether the SmPGS, a composite
measure of 2623 smoking-related DNA methylation sites,
predicts differences in global gene expression by con-
ducting transcriptome-wide analysis of the SmPGS in
Dunedin study participants at age-38. This analysis
identified 143 differentially expressed probesets within 98
genes (Supplementary Table S2.). Pathway analysis
revealed that networks related to cellular movement,
immune cell trafficking, hematological system develop-
ment and function, cell-mediated immune response, and
inflammatory response were the most significantly enri-
ched for these genes (Supplementary Table S3.).
We then asked whether individual DNA methylation
probes were responsible for these associations by decon-
structing the SmPGS. We conducted integrative genomic
analysis by testing correlations between methylation levels
at the 2623 DNA methylation probes included in the
SmPGS and expression levels of the 143 gene expression
probesets. To investigate any possible underlying biolo-
gical relationship between these correlated methylation
probes and expression probesets, we conducted this
analysis separately in two groups of individuals: those who
currently smoke and those who have never smoked. This
rationale deems that if a relationship between DNA
methylation and gene expression is not dependent solely
on shared influence of smoking, then it should be
observable both in individuals who have never smoked as
well as in those who have. If the relationship is driven by
smoking, then it would be observable in just one of these
groups. Of the 375,089 correlations tested, 108 were sig-
nificant after Bonferroni correction (p < 1.33 × 10-7) in
both non-smokers and smokers, representing 47 unique
DNA methylation probes and 22 unique gene expression
probesets in 14 genes (Supplementary Table S4.).
Most of the correlations between DNA methylation
probes and expression probesets identified above describe
trans relationships; only one of the 47 DNA methylation
probes was cis (defined as 250 Kb up- or down-stream of
the start of a gene) to a correlated probeset, cg26724967
located 124 bp upstream of the start of IL32. This DNA
methylation probe is negatively correlated with four
probesets indexing IL32 gene expression (Fig. 3). IL32 is
an inflammatory cytokine that has been previously asso-
ciated with COPD and smoking-related damage to the
lungs25,26. Cis relationships between DNA methylation
and IL32 expression have been previously observed in
smokers2, but it is not clear that the relationship is
independent of smoking; here we document cis relation-
ships in non-smokers, which suggests the potential for a
causal biological effect of proximal DNA methylation on
IL32 expression independent of smoking. IL32 is an
excellent candidate for understanding the biological
impact of DNA methylation on disease risk.
As a sensitivity analysis, we entertained the possibility
that methylation-expression correlations among non-
smokers arise because of passive exposure to second-
hand smoking that exerts similar effects to the direct
consumption of tobacco products. We repeated the cor-
relation analyses in the never-smoker group while con-
trolling for self-reports of exposure to second-hand
smoke (for example, in the home or workplace). The
magnitude and direction of correlations between DNA
methylation probes and gene expression probesets were
comparable to the non-adjusted correlation statistics
(spearman’s rho= 0.99, p < 0.001, Supplementary Table
S4), suggesting the observed associations reflect biological
relationships not driven by underlying passive tobacco
consumption.
C: Methylation polygenic score changes between 26 and
38 years track smoking-associated damage to lungs and
gums
Our longitudinal analysis in the Dunedin cohort sup-
ports the hypothesis that SmPEGS tracks the accumula-
tion of tobacco exposure and SmPEGS becomes
attenuated over time among those who quit smoking. An
important question, therefore, is whether SmPEGS
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reflects processes of smoking-associated physiological
damage and recovery.
We considered damage to two systems proximate to
tobacco exposure: the lungs and the gums. Our analysis of
lung and gum damage used longitudinal data collected at
the same time as DNA methylation. Lung function was
measured at age-26 and 38 years using the carbon mon-
oxide transfer coefficient DLco/VA (in mL/min/mmHg/L),
an index of the efficiency of alveolar transfer of carbon
monoxide; lower values index worse lung function. Gum
health was measured at ages 26 and 38 years as periodontal
attachment loss in mm; higher values index worse gum
health.
Lung function
Study members who smoked at ages 26 and 38 years
suffered damage to their lungs. Current-smokers at age-
26 had DLco/VA measures 0.28 units lower than never-
smokers, and at age-38 current-smokers had measures
0.83 units lower than never-smokers. Longitudinally, we
find that within-individual changes in pack-years accu-
mulation tracked with within-individual changes in lung
function. Among those who had ever smoked, each
additional pack-year smoked was associated with a 0.03-
SD unit decline in DLco/VA [95%CI 0.01–0.05] (Fig. 4a).
In parallel, we tested whether study members’ SmPEGS
was associated with lung damage. Each additional
Fig. 3 Diagrammatic representation of the region surrounding the transcription start site of IL32. DNA methylation levels of probe
cg26724967 (a constituent of the SmPGS) are negatively correlated with IL32 gene expression levels in the Dunedin Study. Shown are the locations of
all 450K array DNA methylation probes in this region (based on genome assembly hg19), with cg26724967 highlighted in red. Each of the four
following rows represent the four available probesets for IL32 on the Affymetrix PrimeView array, and the blue bars indicate the magnitude of the
negative correlation between each probeset and DNA methylation probe in the Dunedin Study. All DNA methylation probes in this region show
high negative correlations with IL32 expression, suggesting a role in IL32 gene regulation. For illustrative purposes, patterns of H3K27Ac marks
(indicative of enhancer regions) and transcription factor binding site (TFBS) data from the ENCODE project are shown at the bottom of the plot; peaks
of histone modification and multiple ChIP-seq identified TFBS in this location support the hypothesis that the region is important for gene regulation
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SmPEGS SD unit increase was associated with a 0.23-SD
unit decline in DLco/VA [95% CI 0.10–0.36] (Fig. 4b).
Gum health
Study members who smoked at ages 26 and 38 years
suffered damage to their gums. Current-smokers at age-
26 had 0.13 mm more periodontal attachment loss than
never-smokers, and at age-38 current-smokers had
0.77 mm more periodontal attachment loss than never-
smokers. Longitudinally, we find that within-individual
changes in pack-years accumulation tracked with within-
individual changes in periodontal attachment loss. Among
those who had ever smoked, each additional pack-year
smoked was associated with 0.07 mm of additional peri-
odontal attachment loss [95% CI 0.05–0.08] (Fig. 4c). In
parallel, we tested whether study members’ SmPEGS was
associated with gum damage. Each additional SmPEGS
SD unit increase was associated with 0.17 millimeters of
additional periodontal attachment loss [95% CI 0.06–0.28]
(Fig. 4d).
These findings suggest that not only does the SmPEGS
track smoking, but also smoking-related damage to bio-
logical systems. This damage is detectable external to the
tissue of clinical interest, namely the lungs and gums. The
Fig. 4 Association between change in pack-years smoked or SmPEGS and change in smoking-associated damage to lungs and gums between ages
26 and 38 in the Dunedin Study. (a) and (c) show change in pack-years versus change in lung function and peridontal attachement loss, repectively.
(b) and (d) show change in SmPEGS and change in lung function and periodontal attachment loss, respectively. The analysis is restricted to study
members who smoked between ages 26 and 38 years
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SmPEGS, measurable in a blood sample, may serve as a
suitable proxy when invasive or complicated testing are
not feasible.
D: Cigarette smoking confounds associations between
psychosocial risk factors and DNA methylation
Adverse experiences in childhood are associated with
increased morbidity and early mortality16. Epigenetic
modifications are thought to play a role in this apparent
“biological embedding” of risk27–29. However, adverse
childhood experiences (ACEs) are also associated with
smoking behavior30, making it difficult to tease apart
epigenetic associations with early stress from the effects of
smoking on the epigenome31.
We conducted EWAS of reports of ACEs in the
Dunedin and E-Risk studies. In both cohorts, we mea-
sured ACEs as the sum of exposure to ten types of
childhood experiences. ACEs predicted differential DNA
methylation at ten probes in the Dunedin Study and seven
in the E-Risk Study. However, each one of these probes
was associated with smoking in our Dunedin and E-Risk
studies, and in the study by Joehanes et al.2. After statis-
tical control for number of pack-years smoked, no probes
remained statistically significantly associated with ACEs
in the Dunedin Study and only one probe (cg25949550)
remained significant in the E-Risk Study (Supplementary
Table S5).
We further tested if including the SmPEGS as a cov-
ariate would yield a similar pattern of attenuation to that
observed when including smoking history as a covariate.
We found that comparable statistical control for smoking
could be achieved using the SmPEGS (Fig. 5). Statistical
control for smoking history is vital when conducting
epigenetic analyses of ACEs, and if a study lacked
observed smoking history data, the SmPEGS could serve
as a suitable proxy control.
Discussion
We demonstrated that DNA methylation patterns in
whole blood are associated with tobacco smoking, and
that composite scores comprising specific DNA methy-
lation sites (SmPEGS) can be utilized to index smoking
behavior. SmPEGS are higher in smokers than non-
smokers, are observable in both middle-aged individuals
(Dunedin Study members) and young adults (E-Risk
Study members), increase with additional tobacco con-
sumption, and subside upon smoking cessation. In par-
allel with smoking, changes in SmPEGS over time index
changes in lung function and gum health. Lastly, tobacco
smoking confounds DNA methylation studies of psy-
chosocial risk, and this can be accounted for by introdu-
cing either observed smoking history or SmPEGS as a
statistical control.
There are a number of implications of SmPEGS. First,
analysis of twins in the E-Risk Study shows that, while
there is substantial familiality to SmPEGS, the association
with smoking cannot be fully accounted for by either
genetics or shared environmental effects. This is in line
with several smaller twin studies that have focused on
DNA methylation at individual probe sites32,33, and other
research that demonstrates that while methylation
Quantitative Trait Loci (mQTLs) for smoking-related
probes exist, a substantial amount are independent of
genetic correlates34. These observations combined sug-
gest that smoking might elicit effects on DNA methyla-
tion independent of background risk associated with an
individual’s genetic or environmental propensity for
smoking.
Second, changes in SmPEGS parallel smoking behavior
changes; Dunedin Study members who continued to
smoke between age-26 and age-38 saw a corresponding
increase in their SmPEGS between assessments, while
those who ceased smoking over the same period saw a
relative decline in their SmPEGS. Dynamic responses of
DNA methylation levels to changes in smoking behavior
are of particular significance to public health; if DNA
methylation changes represent clinically relevant indica-
tors of damage arising from tobacco use, then their
reversal after ceasing tobacco use suggests the potential
for biological recovery. Previous studies have demon-
strated that CpG site-specific DNA methylation has the
potential for long-term recovery via time-since-quit
models of analysis2,5, although the results are not con-
sistent4,8,35,36. Here, using within-person changes in
smoking behavior mapped to within-person changes in
SmPEGs, we show that there is potential for recovery at
the aggregate level.
Third, a number of DNA methylation sites that com-
prise SmPEGS predict corresponding changes in gene
expression. These differentially expressed genes are found
in pathways relating to inflammation, immune response,
and cellular trafficking, indicating smoking-induced DNA
methylation differences might exert an effect via inflam-
matory pathways. Moreover, a proportion of these cor-
relations are observed in those who do not smoke,
suggesting these DNA methylation-gene expression rela-
tionships are not artefacts of smoking behavior. That
these DNA methylation sites were initially identified
through differential methylation patterns in response to
smoking gives rise to possible routes by which smoking
exerts biological damage at the molecular level. Of par-
ticular interest is the DNA methylation probe
cg26724967, negatively correlated in cis to IL32 expres-
sion. IL32 is a relatively recently discovered cytokine, and
previous research has shown that IL32mRNA and protein
levels in serum and lung tissue are higher in smokers with
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chronic pulmonary obstructive disease (COPD) than non-
smoking COPD patients, non-COPD smokers, and heal-
thy controls25,26. IL32 is an excellent candidate biomarker
for smoking-induced damage to health, and warrants
further investigation.
Fourth, changes in SmPEGS index changes in lung
function and gum health over time; these changes are
comparable to those predicted by changes in amount of
cigarettes smoked over the same period. This suggests
SmPEGS can be utilized to index damage to distal bio-
logical systems (in this case, the lungs and gums) without
necessitating collection of said tissue. Evidence exists that
some of these smoking-sensitive DNA methylation sites
can also be identified in lung tissue37,38, and further
research on the link between DNA methylation in blood
and damage to distal biological systems could uncover
novel biomarkers of health39.
The final implication concerns future study design40,41.
Epigenome-wide association studies strive to remove
effects of confounding covariates42 when the confounding
factor is robustly associated with (a) the exposure/phe-
notype under test, and with (b) differential DNA methy-
lation. These two points are relevant in studies of
psychosocial stress, which are vigorously interrogating
how “stress gets under the skin”. A difficulty is that
individuals who have higher levels of stress smoke more30,
and smoking itself elicits differential effects on the epi-
genome. Here, we show that in the case of adverse
childhood experiences (ACEs), smoking confounds tests
of the association with DNA methylation. When testing
Fig. 5 Cigarette smoking confounds associations between psychosocial risk factors and DNA methylation. a, b show the scatterplot of the
–Log10(p) values from an epigenome-wide association studies (EWAS) of adverse childhood experiences (ACEs; x-axis) plotted against –Log10(p) from
an EWAS of ACEs controlling for pack-years smoked at age-38 in the Dunedin Study (a) and age-18 in the E-Risk Study (b). c, d show the same
scatterplot but substituting SmPEGS at age-38 in Dunedin (c) and age-18 in E-Risk (d) for pack-years smoked. Dashed lines represent the genome-
wide significant cutoff levels. Blue points represent probes significant in the EWAS of ACEs. Had EWAS hits for ACEs remained significant after
controlling for smoking (a, b) or for Smoking methylation Polygenic Score (SmPEGS) (c, d), the blue points would appear in the upper right-hand
quadrant. In both cohorts, controlling for smoking or using the SmPEGS attenuates the association between ACEs and DNA methylation to non-
significance; hence the blue points appear in the lower right-hand quadrant
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associations between DNA methylation and a phenotype
known to be also associated with smoking (e.g., schizo-
phrenia, alcoholism, hypertension43,44), statistical control
for smoking behavior should be introduced. Where a
subject’s smoking history is undetermined or potentially
unreliable7, SmPEGS can be utilized successfully in its
place. Some researchers have started to use polyepigenetic
scores to index smoking, but they are developing these
scores in idiosyncratic and sample specific ways. This is
likely to impede the systematic accumulation of knowl-
edge. Thus, here we have developed a standard metho-
dology for creating polyepigenetic scores. Importantly,
this framework of score construction can be extended to
any measure associated with both an exposure and DNA
methylation so as to generate proxy controls for con-
founders where necessary.
There are some caveats. First, we took a conservative
approach to constructing SmPEGS by utilizing only the
2623 probes that reached genome-wide significance (p <
1 × 10-07) in Joehanes et al.2. While this approach of
restricting candidate markers to those with association p-
value less than a defined threshold is common in the
polygenic scoring community45,46, it is possible we omit-
ted some biologically relevant variation in smoking-
related DNA methylation not captured by this list of
probes. However, as shown in Supplementary Materials
(Supplementary Table S6), we also constructed a score
utilizing all 18,760 probes that reached False Discovery
Rate (FDR)-level significance in Joehanes et al.2. This
score predicted smoking no better than the SmPEGS. In
contrast to the polyepigenetic approach, a primary focus
of previous biomarker development has been the single
CpG probe cg05575921, located within the gene AHRR.
Indeed, consistent with prior reports, methylation beta
levels of this one probe do an excellent job of dis-
criminating never-, former-, and current-smokers and is
associated with cumulative smoking exposure in our
data6,7,47 (Supplementary Table S6). Reported associations
between cg05575921 and smoking are not always con-
sistent; for example, evidence of rebound to non-smoking
levels after quitting is conflicting35,36,48, and evidence of
association with dependence-associated behavior is lack-
ing6. To this end, it is possible that a polyepigenetic
approach to assessing smoking dynamics could better
capture divergent underlying biological correlates of
smoking, such as nicotine craving, that a single DNA
methylation signal does not. Second, we constructed
SmPEGS in blood DNA; we are unable to verify whether
SmPEGS are generalizable across different tissue types. It
is likely that the tissue specificity of DNA methylation
levels varies across the range of probes used to construct
the SmPEGS49. We encourage the validation of cross-
tissue applicability when substrates other than blood are
used. That said, given that most population-based
assessments of DNA methylation are made using DNA
from blood, the algorithm for construction of SmPEGS
described herein has broad-scale utility for the majority of
researchers. Third, we borrowed the idea of a poly-
epigenetic score from the methods employed by the
GWAS community, and we assume that the effects are
additive. As in this cognate area46, this assumption will
require validation and interrogation.
In conclusion, we describe the construction of a DNA
methylation composite score that indexes smoking
behavior, predicts damage to biological systems known to
be affected by smoking, is correlated with changes in gene
expression, and can be utilized as a proxy smoking-history
measure in situations where observational smoking data
are unavailable.
Acknowledgements
The Dunedin Longitudinal Study is funded by the New Zealand Health
Research Council, the New Zealand Ministry of Business, Innovation, and
Employment, the National Institute on Aging (AG032282), and the Medical
Research Council (MR/P005918/1). The E-Risk Study is funded by the Medical
Research Council (G1002190) and the National Institute of Child Health and
Human Development (HD077482). Additional support was provided by a
Distinguished Investigator Award from the American Asthma Foundation to
Dr. Mill, and by the Jacobs Foundation and the Avielle Foundation. Dr.
Arseneault is the Mental Health Leadership Fellow for the U.K. Economic and
Social Research Council. Dr. Belsky is a Jacobs Foundation Fellow. This work
used a high-performance computing facility partially supported by grant 2016-
IDG-1013 (“HARDAC+ : Reproducible HPC for Next-generation Genomics”)
from the North Carolina Biotechnology Center. Illumina DNA methylation data
are accessible from the Gene Expression Omnibus (accession code:
GSE105018). We thank the Dunedin and E-Risk Study members, research staff,
and Dunedin Study founder Phil Silva.
Author details
1Department of Psychology and Neuroscience, Duke University, Durham, NC,
USA. 2Center for Genomic and Computational Biology, Duke University,
Durham, NC, USA. 3University of Exeter Medical School, University of Exeter,
Exeter, UK. 4Social, Genetic, and Developmental Psychiatry Research Centre,
Institute of Psychiatry, Psychology, and Neuroscience, King’s College London,
London, UK. 5Department of Epidemiology & Butler Aging Center, Columbia
University Mailman School of Public Health, New York, NY, USA. 6Department
of Oral Sciences, University of Otago, Dunedin, New Zealand. 7Department of
Preventive and Social Medicine, Dunedin School of Medicine, University of
Otago, Dunedin, New Zealand. 8Department of Psychiatry and Behavioral
Sciences, Duke University School of Medicine, Durham, NC, USA. 9Dunedin
Multidisciplinary Health and Development Research Unit, University of Otago,
Dunedin, New Zealand
Conflict of interest
The authors declare that they have no conflict of interest.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Supplementary Information accompanies this paper at (https://doi.org/
10.1038/s41398-019-0430-9).
Received: 15 November 2018 Revised: 17 January 2019 Accepted: 24
January 2019
Sugden et al. Translational Psychiatry            (2019) 9:92 Page 11 of 12    92 
References
1. U.S. Department of Health and Human Services, Centers for Disease Control
and Prevention, National Center for Chronic Disease Prevention and Health
Promotion, Office on Smoking and Health. The Health Consequences of
Smoking-50 Years of Progress: A Report of the Surgeon General (U.S. Department
of Health and Human Services, Atlanta, GA, 2014).
2. Joehanes, R. et al. Epigenetic signatures of cigarette smoking. Circ. Cardiovasc
Genet. 9, 436–447 (2016).
3. Gao, X., Jia, M., Zhang, Y., Breitling, L. P. & Brenner, H. DNA methylation
changes of whole blood cells in response to active smoking exposure in
adults: a systematic review of DNA methylation studies. Clin. Epigenetics. 7, 113
(2015).
4. Tsaprouni, L. G. et al. Cigarette smoking reduces DNA methylation levels at
multiple genomic loci but the effect is partially reversible upon cessation.
Epigenetics 9, 1382–1396 (2014).
5. Zeilinger, S. et al. Tobacco smoking leads to extensive genome-wide changes
in DNA methylation. PLoS ONE 8, e63812 (2013).
6. Philibert, R. et al. Dose response and prediction characteristics of a methylation
sensitive digital PCR assay for cigarette consumption in adults. Front. Genet. 9,
137 (2018).
7. Andersen, A. M., Philibert, R. A., Gibbons, F. X., Simons, R. L. & Long, J. Accuracy
and utility of an epigenetic biomarker for smoking in populations with varying
rates of false self-report. Am. J. Med Genet. B Neuropsychiatr. Genet. 174,
641–650 (2017).
8. Shenker, N. S. et al. DNA methylation as a long-term biomarker of exposure to
tobacco smoke. Epidemiology 24, 712–716 (2013).
9. Ladd-Acosta, C. et al. Presence of an epigenetic signature of prenatal cigarette
smoke exposure in childhood. Environ. Res. 144(Pt A), 139–148 (2016).
10. Reese, S. E. et al. DNA methylation score as a biomarker in newborns for
sustained maternal smoking during pregnancy. Environ. Health Perspect. 125,
760–766 (2017).
11. Richmond, R. C., Suderman, M., Langdon, R., Relton, C. L. & Davey Smith, G.
DNA methylation as a marker for prenatal smoke exposure in adults. Int J.
Epidemiol. 47, 1120–1130 (2018).
12. Zhang, Y. et al. Smoking-associated DNA methylation biomarkers and their
predictive value for all-cause and cardiovascular mortality. Environ. Health
Perspect. 124, 67–74 (2016).
13. Poulton, R., Moffitt, T. E. & Silva, P. A. The Dunedin Multidisciplinary Health and
Development Study: overview of the first 40 years, with an eye to the future.
Soc. Psychiatry Psychiatr. Epidemiol. 50, 679–693 (2015).
14. Moffitt, T. E., Team ERS. Teen-aged mothers in contemporary Britain. J. Child
Psychol. Psychiatry 43, 727–742 (2002).
15. Graham, B. L. et al. 2017 ERS/ATS standards for single-breath carbon monoxide
uptake in the lung. Eur. Respir. J. 49, 1600016 (2017). https://doi.org/10.1183/
13993003.00016-2016.
16. Felitti, V. J. et al. Relationship of childhood abuse and household dysfunction
to many of the leading causes of death in adults. The Adverse Childhood
Experiences (ACE) Study. Am. J. Prev. Med. 14, 245–258 (1998).
17. Belsky, D. W. et al. Polygenic risk and the developmental progression to heavy,
persistent smoking and nicotine dependence: evidence from a 4-decade
longitudinal study. JAMA Psychiatry 70, 534–542 (2013).
18. Hannon, E. K. O. et al. Characterizing genetic and environmental influences on
variable DNA methylation using monozygotic and dizygotic twins. PLoS Genet.
14, e1007544 (2018).
19. Polderman, T. J. et al. Meta-analysis of the heritability of human traits based on
fifty years of twin studies. Nat. Genet. 47, 702–709 (2015).
20. Fagerstrom, K. O. Measuring degree of physical dependence to tobacco
smoking with reference to individualization of treatment. Addict. Behav. 3,
235–241 (1978).
21. Boyes, J. & Bird, A. DNA methylation inhibits transcription indirectly via a
methyl-CpG binding protein. Cell 64, 1123–1134 (1991).
22. Jaenisch, R. & Bird, A. Epigenetic regulation of gene expression: how the
genome integrates intrinsic and environmental signals. Nat. Genet. 33(Suppl),
245–254 (2003).
23. Wan, J. et al. Characterization of tissue-specific differential DNA methylation
suggests distinct modes of positive and negative gene expression regulation.
BMC Genom. 16, 49 (2015).
24. Anastasiadi, D., Esteve-Codina, A. & Piferrer, F. Consistent inverse correlation
between DNA methylation of the first intron and gene expression across
tissues and species. Epigenetics Chromatin. 11, 37 (2018).
25. Gasiuniene, E., Lavinskiene, S., Sakalauskas, R. & Sitkauskiene, B. Levels of IL-32 in
serum, induced sputum supernatant, and bronchial lavage fluid of patients
with chronic obstructive pulmonary disease. COPD 13, 569–575 (2016).
26. Calabrese, F. et al. IL-32, a novel proinflammatory cytokine in chronic
obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 178, 894–901
(2008).
27. Suderman, M. et al. Childhood abuse is associated with methylation of mul-
tiple loci in adult DNA. BMC Med Genom. 7, 13 (2014).
28. Vaiserman, A. M. Epigenetic programming by early-life stress: Evidence from
human populations. Dev. Dyn. 244, 254–265 (2015).
29. Klengel, T. & Binder, E. B. Epigenetics of stress-related psychiatric disorders and
gene x environment interactions. Neuron 86, 1343–1357 (2015).
30. Anda, R. F. et al. Adverse childhood experiences and smoking during ado-
lescence and adulthood. JAMA 282, 1652–1658 (1999).
31. Marzi, S. J. et al. Analysis of DNA methylation in young people: Limited
evidence for an association between victimization stress and epigenetic var-
iation in blood. Am. J. Psychiatry 175, 517–529 (2018).
32. Allione, A. et al. Novel epigenetic changes unveiled by monozygotic twins
discordant for smoking habits. PLoS ONE 10, e0128265 (2015).
33. Li, S. et al. Causal effect of smoking on DNA methylation in peripheral blood: a
twin and family study. Clin. Epigenetics. 10, 18 (2018).
34. Gao, X., Thomsen, H., Zhang, Y., Breitling, L. P. & Brenner, H. The impact of
methylation quantitative trait loci (mQTLs) on active smoking-related DNA
methylation changes. Clin. Epigenetics. 9, 87 (2017).
35. Guida, F. et al. Dynamics of smoking-induced genome-wide methylation
changes with time since smoking cessation. Hum. Mol. Genet. 24, 2349–2359
(2015).
36. Wilson, R. et al. The dynamics of smoking-related disturbed methylation: a two
time-point study of methylation change in smokers, non-smokers and former
smokers. BMC Genom. 18, 805 (2017).
37. Shenker, N. S. et al. Epigenome-wide association study in the European
Prospective Investigation into Cancer and Nutrition (EPIC-Turin) identifies
novel genetic loci associated with smoking. Hum. Mol. Genet. 22, 843–851
(2013).
38. Stueve, T. R. et al. Epigenome-wide analysis of DNA methylation in lung tissue
shows concordance with blood studies and identifies tobacco smoke-
inducible enhancers. Hum. Mol. Genet. 26, 3014–3027 (2017).
39. Ladd-Acosta, C. & Fallin, M. D. The role of epigenetics in genetic and envir-
onmental epidemiology. Epigenomics 8, 271–283 (2016).
40. Birney, E., Smith, G. D. & Greally, J. M. Epigenome-wide Association Studies and
the Interpretation of Disease -Omics. PLoS Genet. 12, e1006105 (2016).
41. Mill, J. & Heijmans, B. T. From promises to practical strategies in epigenetic
epidemiology. Nat. Rev. Genet. 14, 585–594 (2013).
42. Terry, M. B., Delgado-Cruzata, L., Vin-Raviv, N., Wu, H. C. & Santella, R. M. DNA
methylation in white blood cells: association with risk factors in epidemiologic
studies. Epigenetics 6, 828–837 (2011).
43. Cook, B. L. et al. Trends in smoking among adults with mental illness and
association between mental health treatment and smoking cessation. JAMA
311, 172–182 (2014).
44. Niskanen, L. et al. Inflammation, abdominal obesity, and smoking as predictors
of hypertension. Hypertension 44, 859–865 (2004).
45. Dudbridge, F. Power and predictive accuracy of polygenic risk scores. PLoS
Genet. 9, e1003348 (2013).
46. Wray, N. R. et al. Research review: Polygenic methods and their application to
psychiatric traits. J. Child Psychol. Psychiatry 55, 1068–1087 (2014).
47. Philibert, R. A., Beach, S. R., Lei, M. K. & Brody, G. H. Changes in DNA methy-
lation at the aryl hydrocarbon receptor repressor may be a new biomarker for
smoking. Clin. Epigenetics. 5, 19 (2013).
48. Philibert, R. et al. Reversion of AHRR demethylation is a quantitative biomarker
of smoking cessation. Front. Psychiatry 7, 55 (2016).
49. Hannon, E., Lunnon, K., Schalkwyk, L. & Mill, J. Interindividual methylomic
variation across blood, cortex, and cerebellum: implications for epigenetic
studies of neurological and neuropsychiatric phenotypes. Epigenetics 10,
1024–1032 (2015).
Sugden et al. Translational Psychiatry            (2019) 9:92 Page 12 of 12    92 
